Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Category : Search result: India pharmaceutical industry
India Plans New Pharma Licence for Bulk Drugs to Boost Safety
India plans a major pharma licensing overhaul with a separate wholesale licence for bulk drugs and APIs to improve traceability and safety. This move follows global scrutiny over contaminated cough syrups and aims to regulate a $50-billion market.
Indian Pharma's Innovation Success in 2025
Indian pharmaceutical companies, long known for generics, saw their risky innovation bets yield major commercial success in 2025 through global deals and approvals. Discover the key players and what's next for 2026.
India's New Pharma Licence Regime to Fix Accountability
India plans a new wholesale licensing system for bulk drugs and a supplier database to enhance traceability and accountability in its $50-billion pharmaceutical market, following global safety concerns.
Karnal Pharma Park Delays Leave Drug Makers in Limbo
Pharmaceutical manufacturers in Haryana await land allocation for the Karnal Pharma Park, a project delayed since 2021. The park promises to boost drug production and exports. Read about the industry's demands and government's plans.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Aurobindo Pharma buys Khandelwal Labs unit for ₹325 cr
Aurobindo Pharma strengthens its domestic formulations market with a ₹325 crore acquisition of Khandelwal Laboratories' non-oncology business. The deal includes 23 established brands and boosts presence in pain & anti-infective segments. Read more.
Drug Inspection Data Kept Secret, Public Safety at Risk?
India's drug regulator CDSCO refuses to disclose risk-based inspection details under RTI, sparking debate on transparency vs. commercial interests. Experts warn this secrecy endangers public health.
Fermenta Biotech Ranked Among India's Best Workplaces
Fermenta Biotech Ltd. has been recognized as one of India's Best Workplaces in Pharmaceuticals, Healthcare & Biotech 2024 by Great Place To Work. Discover what makes their culture stand out.
India's 2026 Health Agenda: Drug Quality, TB, Innovation
India sets a 2026 health roadmap focusing on stringent drug quality, TB elimination, obesity, and a ₹4,200 crore innovation push. Will execution match ambition?
Everfast Strengthens India's Medicine Cold Chain Capabilities
Everfast Freight Forwarders launches a major cold chain expansion in India, enhancing storage for medicines and vaccines. Discover how this investment supports healthcare logistics.
JioHotstar Series Questions India's Pharmaceutical System
JioHotstar's new series 'Pharma' ignites public debate on drug pricing, ethics, and accessibility in India's healthcare system. Read the full analysis.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Govt's Data Exclusivity Push May Hit Cheap Generic Drugs
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
IndiaRF begins $250-300M stake sale in Synthimed Labs
India Resurgence Fund has launched a process to sell a minority stake in API maker Synthimed Labs, targeting a $1 billion valuation. Read the full details on the deal and the company's growth.
Afghanistan Picks India Over Pakistan for Pharma Supplies
Afghan Health Minister admits strained Pakistan ties, pivots to India for reliable medicine and vaccine supplies. A major shift in regional health diplomacy unfolds. Read the full analysis.
Trump's Deal with 9 Pharma Firms to Cut US Drug Prices
US President Donald Trump secures agreements with nine major pharmaceutical companies to reduce Medicaid and cash-pay drug prices, aiming to align US costs with other wealthy nations. Details inside.
Govt Imposes Price Floor on Drug APIs to Curb Cheap Imports
Himachal Pradesh govt introduces Minimum Import Price on potassium clavulanate & intermediates till Nov 2026 to shield Indian API makers from cheap Chinese imports. Read details.
Nivin Pauly's Pharma Web Series Premieres Dec 19 on JioHotstar
Malayalam star Nivin Pauly headlines 'Pharma', a hard-hitting web series on the dark side of the pharmaceutical industry. Premieres December 19, 2025, on JioHotstar in 5 languages.
Odisha Pharma Summit 2025 garners Rs 7,043 crore proposals
Odisha CM Mohan Majhi positions state as top pharma & medical devices investment destination. New policy & parks attract Rs 7,043 crore proposals, 45 MoUs signed. Read more.
Shark Tank's Mittal on Ozempic Launch & 2026 Pharma Shift
Shark Tank India's Anupam Mittal comments on Ozempic's India launch, its ₹8,800/month price, and the 2026 patent expiry that could 5x the market. Read his take on fitness shortcuts vs. discipline.
Himachal Pharma Sector Faces Major Trust Crisis
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's 'Pharma' Trailer Targets Unethical Drug Practices
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Govt Audits 700+ Cough Syrup Makers, Tests 19 Samples
Indian government intensifies scrutiny on pharmaceutical sector, auditing 700+ cough syrup manufacturers. Health Ministry reveals 19 drug samples collected for testing amid child safety concerns. Read the full report.
Granules India sets up two R&D centres at IIT Hyderabad
Granules India establishes two advanced research centres at IIT Hyderabad's Technology Research Park, focusing on peptide development and particle engineering to enhance global pharma innovation.
Wockhardt's Zaynich NDA Accepted by USFDA, Shares Soar 19%
Mumbai's Wockhardt creates history as USFDA accepts its New Drug Application for antibiotic Zaynich, a first for an Indian firm. Shares surge 19%. Read more.
Wockhardt Stock Jumps on US FDA Nod for Novel Antibiotic
Wockhardt shares surged 19.3% after US FDA accepted its New Drug Application for Zaynich, a first-in-class antibiotic. This marks a historic first for an Indian pharma company's New Chemical Entity.
Freudenberg's Pharma Innovations at CPhI PMEC India 2025
Freudenberg Medical & Filtration Technologies unveil cutting-edge pharmaceutical solutions at CPhI PMEC India 2025, featuring advanced single-use systems and filtration technologies.
Freudenberg Highlights Pharma Innovations at CPhI PMEC 2025
Freudenberg Medical & Filtration Technologies unveil cutting-edge pharmaceutical solutions at CPhI PMEC India 2025, featuring advanced drug delivery systems and filtration technologies.
Page 1 of 4